An Exploratory, Multi-Center, Randomized, Single-Masked Study Evaluating the Effect of KPI-121 on Intraretinal or Subretinal Fluid Secondary to Retinal Vein Occlusion or Diabetic Macular Edema

Trial Profile

An Exploratory, Multi-Center, Randomized, Single-Masked Study Evaluating the Effect of KPI-121 on Intraretinal or Subretinal Fluid Secondary to Retinal Vein Occlusion or Diabetic Macular Edema

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Apr 2015

At a glance

  • Drugs Loteprednol etabonate (Primary)
  • Indications Diabetic macular oedema; Retinal vein occlusion
  • Focus Therapeutic Use
  • Acronyms Molokini
  • Sponsors Kala Pharmaceuticals
  • Most Recent Events

    • 30 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 24 Nov 2014 Planned primary completion date changed from 1 Nov 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
    • 24 Nov 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top